S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

$57.34
-1.03 (-1.76%)
(As of 03/18/2024 ET)
Today's Range
$57.30
$58.75
50-Day Range
$57.34
$64.38
52-Week Range
$50.27
$76.04
Volume
1.81 million shs
Average Volume
1.73 million shs
Market Capitalization
$12.87 billion
P/E Ratio
21.64
Dividend Yield
N/A
Price Target
$76.20

Incyte MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
30.9% Upside
$75.07 Price Target
Short Interest
Healthy
3.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.63mentions of Incyte in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$42,705 Sold Last Quarter
Proj. Earnings Growth
25.85%
From $3.83 to $4.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

9th out of 947 stocks

Commercial Physical Research Industry

1st out of 11 stocks

INCY stock logo

About Incyte Stock (NASDAQ:INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Stock Price History

INCY Stock News Headlines

8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
My next big prediction isn’t a prediction
I believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.
5 Biotech Stocks with Huge Potential
Q4 2023 Syndax Pharmaceuticals Inc Earnings Call
Incyte: A Potential GARP Superstar
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/18/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,524
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$75.07
High Stock Price Target
$93.00
Low Stock Price Target
$61.00
Potential Upside/Downside
+32.9%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
16 Analysts

Profitability

Net Income
$597.60 million
Pretax Margin
22.57%

Debt

Sales & Book Value

Annual Sales
$3.70 billion
Cash Flow
$2.39 per share
Book Value
$23.16 per share

Miscellaneous

Free Float
185,234,000
Market Cap
$12.87 billion
Optionable
Optionable
Beta
0.65

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives


INCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 9 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price target for 2024?

16 brokerages have issued 12-month price objectives for Incyte's stock. Their INCY share price targets range from $61.00 to $93.00. On average, they expect the company's stock price to reach $75.07 in the next year. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2024?

Incyte's stock was trading at $62.79 on January 1st, 2024. Since then, INCY shares have decreased by 8.7% and is now trading at $57.34.
View the best growth stocks for 2024 here
.

Are investors shorting Incyte?

Incyte saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 7,770,000 shares, a decline of 10.7% from the February 14th total of 8,700,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is presently 4.2 days.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its earnings results on Tuesday, February, 13th. The biopharmaceutical company reported $1.06 EPS for the quarter, missing the consensus estimate of $1.15 by $0.09. The biopharmaceutical company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Incyte had a trailing twelve-month return on equity of 12.56% and a net margin of 16.17%. The firm's revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.44 earnings per share.
Read the conference call transcript
.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.05%), Vanguard Group Inc. (10.03%), Dodge & Cox (7.17%), LSV Asset Management (1.20%), Bellevue Group AG (0.96%) and Northern Trust Corp (0.88%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INCY) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners